试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-10
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
编号:NCT02914600登记状态:提前终止企业 / 申办者:Lakefront Biotherapeutics NV
药物 / 成分:Filgotinib、Placebo
登记的停止原因(原文):development program for filgotinib for participants with Crohn's disease has been stopped
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-10
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
编号:NCT03088709登记状态:提前终止企业 / 申办者:Loyola University
药物 / 成分:Cyclophosphamide、Tacrolimus、Mycophenolate mofetil、Haploidentical Stem Cell Transplantation
登记的停止原因(原文):Poor accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-10
Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection
编号:NCT03166761登记状态:提前终止企业 / 申办者:Vanderbilt University Medical Center
药物 / 成分:Dexamethasone、Triamcinolone Acetonide
登记的停止原因(原文):recruitment and staffing
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-10
Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
编号:NCT03942601登记状态:提前终止企业 / 申办者:Mercator MedSystems, Inc.
药物 / 成分:Temsirolimus、Temsirolimus and dexamethasone sodium phosphate
登记的停止原因(原文):Halted due to pandemic.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-10
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
编号:NCT04128696登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:feladilimab、Pembrolizumab、Placebo
登记的停止原因(原文):The trial was stopped by the sponsor based on assessment of the clinical data
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-10
Effect of Transcutaneous Auricular Vagal Nerve Stimulation on Chronic Constipation
编号:NCT05723731登记状态:提前终止企业 / 申办者:Air Force Military Medical University, China
药物 / 成分:taVNS、Laxative Agent
登记的停止原因(原文):A pre-specified interim analysis was conducted as planned, we calculated a P-value greater than 0.57 when comparing response rates between taVNS and sham group, resulting in an early termination of the study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-09
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
编号:NCT02096588登记状态:提前终止企业 / 申办者:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
药物 / 成分:Simvastatin、Doxorubicin/cyclophosphamide
登记的停止原因(原文):The Principal Investigator left Johns Hopkins
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-09
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
编号:NCT02400242登记状态:提前终止企业 / 申办者:Celgene
药物 / 成分:ACY-241、Pomalidomide、Dexamethasone
登记的停止原因(原文):Lack of efficacy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-09
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
编号:NCT03439085登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457、Durvalumab
登记的停止原因(原文):Project delays
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-09
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
编号:NCT03770455登记状态:提前终止企业 / 申办者:Jodi Layton, MD
药物 / 成分:Avelumab、2nd generation ADT (abiraterone or enzalutamide)
登记的停止原因(原文):Early signs of progression and learned experience that the assumed time period between psa progression and radiographic progression was shorter than expected
查看官方原始记录 ↗